AIDS deaths worldwide drop as access to drugs improves

Fewer people infected with HIV globally are dying as more of them get access to crucial antiretroviral drugs, particularly in sub-Saharan Africa, the United Nations AIDS program said on Wednesday.

The United Nations estimates that about 34 million people are living with the human immunodeficiency virus (HIV) that causes AIDS. In a report released ahead of the International AIDS Society's 2012 annual meeting set for next week in Washington, D.C., it said that the number of worldwide AIDS-related deaths fell to 1.7 million last year - down from a peak of 2.3 million in 2005 and from some 1.8 million in 2010.

That decline has been fueled by greater access to the medications that help more people live with the disease. An estimated 8 million people in low- and middle-income countries are now receiving antiretroviral drugs, and the United Nations has set a target to raise that to 15 million people by 2015.

"One of the key messages that I believe will come out of the conference is one of optimism and hope that we should be able to achieve the 15 million target by 2015," Dr. Gottfried Hirnschall, director of the HIV Department at the World Health Organization, said during a briefing in Geneva.

Funding for HIV prevention and treatment totaled $16.8 billion last year - $8.2 billion from international sources, with 48 percent donated by the United States. Spending by low- and middle-income countries surpassed international investment for the first time, reaching $8.6 billion. The U.N. estimates that another $5 billion is needed to reach its goals.

Paul De Lay, UNAIDS deputy executive director, said overall progress in treating the disease could be jeopardized by a surge in infection seen in smaller patient groups, including in Eastern Europe and the United States.

"We are looking at an epidemic that's going to last another 40 to 50 years to get down to what we would consider the lowest possible number of infections," De Lay said.

"It reminds us that prevention must be sustained, just the way we talk about sustaining treatment. Until we have a vaccine this is still going to have to be part of all countries' health programs," he said.

SEEKING MORE TREATMENT AND PREVENTION OPTIONS

Public health officials are considering wider use of HIV medications in people who are not infected with the virus but have a high risk of contracting it. Earlier this week, U.S. health regulators for the first time approved use of Gilead Sciences Inc's Truvada drug for preventing HIV.

Such antiretroviral drugs, also sold by companies like GlaxoSmithKline and Merck & Co, are designed to keep the virus that causes AIDS in check by suppressing viral replication in the blood.

Researchers are also at work on using HIV-fighting antibodies to prevent infection, and for the first time in years say the efforts could yield a licensed vaccine.